Sigma-1 receptor and neuroprotection: current outlook and potential therapeutic effects

Sigma-1 receptor and neuroprotection: current outlook and potential therapeutic effects

Bibliographic Details
Main Authors:	Giovanni Li Volti, Paolo Murabito
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2016-01-01
Series:	Neural Regeneration Research
Online Access:	http://www.nrronline.org/article.asp?issn=1673-5374;year=2016;volume=11;issue=9;spage=1392;epage=1393;aulast=Li

Similar Items

Outlook on the neuroprotective effect of estrogen
by: Xavier d'Anglemont de Tassigny
Published: (2017-01-01)

Sigma-1 Receptors in Depression: Mechanism and Therapeutic Development
by: Peng Ren, et al.
Published: (2022-06-01)

Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy
by: Jordi Bruna, et al.
Published: (2018-01-01)

A retrospect and outlook on the neuroprotective effects of anesthetics in the era of endovascular therapy
by: Tianhao Zhang, et al.
Published: (2023-03-01)

Heparan sulfate proteoglycans and heparanases in Alzheimer's disease: current outlook and potential therapeutic targets
by: Laura Lorente-Gea, et al.
Published: (2017-01-01)

Sigma-1 receptor and seizures
by: Edijs Vavers, et al.
Published: (2023-05-01)

The Sigma 2 receptor promotes and the Sigma 1 receptor inhibits mu-opioid receptor-mediated antinociception
by: Pilar Sánchez-Blázquez, et al.
Published: (2020-11-01)

Consequences of hepatic damage after traumatic brain injury: current outlook and potential therapeutic targets
by: Sonia Villapol
Published: (2016-01-01)

Sigma-2 receptor as a potential therapeutic target for treating central nervous system disorders
by: Kazuki Terada, et al.
Published: (2019-01-01)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Current Therapeutic Approaches and Future Outlooks
by: Rajabally YA
Published: (2024-02-01)

The Neuroprotective Effects and Therapeutic Potential of the Chalcone Cardamonin for Alzheimer’s Disease
by: Kimberly Barber, et al.
Published: (2023-01-01)

Potential Benefits of Therapeutic Use of β2-Adrenergic Receptor Agonists in Neuroprotection and Parkinson’s Disease
by: Lynda Peterson, et al.
Published: (2014-01-01)

Neuroprotective Agents with Therapeutic Potential for COVID-19
by: César A. Zaa, et al.
Published: (2023-10-01)

Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan.
by: Linda Nguyen, et al.
Published: (2014-01-01)

Effects of Sigma-1 Receptor Ligands on Peripheral Nerve Regeneration
by: Patrick Cottilli, et al.
Published: (2022-03-01)

The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration
by: Karsten Ruscher, et al.
Published: (2015-01-01)

Role of sigma-1 receptors in neurodegenerative diseases
by: Linda Nguyen, et al.
Published: (2015-01-01)

Free Fatty Acid Receptors (FFARs) in Adipose: Physiological Role and Therapeutic Outlook
by: Saeed Al Mahri, et al.
Published: (2022-02-01)

Cytotoxicity Profiles and Neuroprotective Properties of the Novel Ifenprodil Analogues as Sigma Ligands
by: Daniele Zampieri, et al.
Published: (2023-04-01)

Cocaine Effects on Dopaminergic Transmission Depend on a Balance between Sigma-1 and Sigma-2 Receptor Expression
by: David Aguinaga, et al.
Published: (2018-02-01)

Ayahuasca and its interaction with the sigma-1 receptor: a potential treatment for COVID-19
by: Guillermo Saúl Escobar-Cornejo, et al.
Published: (2022-07-01)

Is the sigma-1 receptor a potential pharmacological target for cardiac pathologies? A systematic review
by: Rebecca Lewis, et al.
Published: (2020-02-01)

A review of the human Sigma-1 Receptor structure
by: Ossa, F, et al.
Published: (2017)

Defining the ligand-dependent proximatome of the sigma 1 receptor
by: Jing Zhao, et al.
Published: (2023-06-01)

Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases
by: Jia Jia, et al.
Published: (2018-09-01)

Characterization of CM-398, a Novel Selective Sigma-2 Receptor Ligand, as a Potential Therapeutic for Neuropathic Pain
by: Lisa L. Wilson, et al.
Published: (2022-06-01)

The Role of Sigma Receptors in Depression
by: Jordanna E. Bermack, et al.
Published: (2005-01-01)

Neuroprotective Potential of Chrysin: Mechanistic Insights and Therapeutic Potential for Neurological Disorders
by: Awanish Mishra, et al.
Published: (2021-10-01)

Neuroprotection as a Therapeutic Target for Diabetic Retinopathy
by: Cristina Hernández, et al.
Published: (2016-01-01)

Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors
by: Hashimoto Kenji, et al.
Published: (2010-03-01)

Pharmacological Interaction With the Sigma1 (σ1)-Receptor in the Acute Behavioral Effects of Antidepressants
by: Vanessa Villard, et al.
Published: (2011-01-01)

Current and further outlook on the protective potential of Antrodia camphorata against neurological disorders
by: Weiling Li, et al.
Published: (2024-04-01)

Sigma-2 receptor ligands QSAR model dataset
by: Antonio Rescifina, et al.
Published: (2017-08-01)

Neuroprotective Effects and Therapeutic Potential of Dichloroacetate: Targeting Metabolic Disorders in Nervous System Diseases
by: Zhang Y, et al.
Published: (2023-12-01)

Docking, Interaction Fingerprint, and Three-Dimensional Quantitative Structure–Activity Relationship (3D-QSAR) of Sigma1 Receptor Ligands, Analogs of the Neuroprotective Agent RC-33
by: José Luis Velázquez-Libera, et al.
Published: (2019-07-01)

Insight into binding of endogenous neurosteroid ligands to the sigma-1 receptor
by: Chunting Fu, et al.
Published: (2024-07-01)

Viewpoints Sigma-1 receptor agonist fluvoxamine for multiple sclerosis
by: Kenji Hashimoto
Published: (2024-05-01)

Sigma 1 Receptor, Cholesterol and Endoplasmic Reticulum Contact Sites
by: Vladimir Zhemkov, et al.
Published: (2021-07-01)

A Perspective on sigma-1 receptor research: Past and future
by: Tsung-Ping Su
Published: (2015-01-01)

Sigma-1 receptor: culprit and rescuer in motor neuron diseases
by: Jean-Charles Lievens, et al.
Published: (2021-01-01)